Guidelines for the prevention of travel-associated illness in older adults
Tóm tắt
Từ khóa
Tài liệu tham khảo
U.S. International Air Travel Statistics Report 2016; Available from: http://travel.trade.gov/view/m-2015-O-001/index.html .
Harvey K, et al. Surveillance for travel-related disease--GeoSentinel Surveillance system, United States, 1997-2011. MMWR Surveill Summ. 2013;62:1–23.
LaRocque RC, et al. Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis. 2012;54(4):455–62.
Ortman JM, Velkoff VA. An Aging Nation: The Older Population in the United States, in Population Estimates and Projections. 2014, The United States Census Bureau. https://www.census.gov/prod/2014pubs/p25-1140.pdf . Accessed 18 May 2017.
Hagmann SH, et al. Travel-associated disease among US residents visiting US GeoSentinel clinics after return from international travel. Fam Pract. 2014;31(6):678–87.
Jaeger VK, et al. The elderly, the young and the pregnant traveler -- a retrospective data analysis from a large Swiss travel center with a special focus on malaria prophylaxis and yellow fever vaccination. Travel Med Infect Dis. 2015;13(6):475–84.
Suh KN, Mileno MD. Challenging scenarios in a travel clinic: advising the complex traveler. Infect Dis Clin N Am. 2005;19(1):15–47.
Levine BD. Going high with heart disease: the effect of high altitude exposure in older individuals and patients with coronary artery disease. High Alt Med Biol. 2015;16(2):89–96.
Patterson JE. The pre-travel medical evaluation: the traveler with chronic illness and the geriatric traveler. Yale J Biol Med. 1992;65(4):317–27.
Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis. 2001;33(9):1553–66.
Matteelli A, Carvalho AC, Bigoni S. Visiting relatives and friends (VFR), pregnant, and other vulnerable travelers. Infect Dis Clin N Am. 2012;26(3):625–35.
Cummins, R.O., et al., In-flight deaths during commercial air travel. How big is the problem? JAMA, 1988. 259(13): p. 1983-1988.
Delaune EF 3rd. R.H. Lucas, and P. Illig, In-flight medical events and aircraft diversions: one airline's experience. Aviat Space Environ Med. 2003;74(1):62–8.
Naouri D, et al. Prevention of medical events during air travel: a narrative review. Am J Med. 2016;129(9):1000 e1–6.
IATA, I.A.T.A., IATA Medical Manual. 2016.
Gautret P, et al. Travel-associated illness in older adults (>60 y). J Travel Med. 2012;19(3):169–77.
Belcaro G, et al. Prevention of venous thrombosis with elastic stockings during long-haul flights: the LONFLIT 5 JAP study. Clin Appl Thromb Hemost. 2003;9(3):197–201.
Clarke MJ, et al. Compression stockings for preventing deep vein thrombosis in airline passengers. Cochrane Database Syst Rev. 2016;9:–CD004002.
Rezzani R, et al. Thymus and aging: morphological, radiological, and functional overview. Age (Dordr). 2014;36(1):313–51.
Weinberger B, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078–84.
Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int. 2009;22(11):1041–50.
Bridges CB, et al. Advisory Committee on immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(5):110–2.
Williams WW, et al. Surveillance of vaccination coverage among adult populations - United States, 2014. MMWR Surveill Summ. 2016;65(1):1–36.
Lu PJ, et al. Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons. MMWR Surveill Summ. 2013;62(4):1–28.
Mutsch M, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis. 2005;40(9):1282–7.
Darvishian M, et al. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis. 2014;14(12):1228–39.
Langley JM, et al. Dose-sparing H5N1 a/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011;203(12):1729–38.
Pasteur, S., 271/371 Fluzone®. 372 Fluzone® High-Dose. 390 Fluzone® Intradermal, in http://www.fda.gov/downloads/biologicsbloodvaccines/.../ucm195479.pdf , S. Pasteur, Editor. 2011. Accessed 18 May 2017.
CDC, Infectious Diseases Related to Travel: Influenza, in Yellowbook. 2016.
Huang SS, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398–412.
Tomczyk S, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822–5.
Harpaz R, et al. Prevention of herpes zoster: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30. quiz CE2-4
Morrison VA, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–9.
Health, C.D.o.P., Pertusis Report. 2015.
Kaml M, et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine. 2006;24(47–48):6808–11.
Zipprich J, et al. Measles outbreak--California, December 2014-February 2015. MMWR Morb Mortal Wkly Rep. 2015;64(6):153–4.
Gastanaduy P, Wallace G. Chapter 3 infectious diseases related to travel: mumps, in Yellowbook: CDC; 2015.
Monath TP, et al. Yellow fever recommendations for tourists to Kenya: a flawed risk assessment. J Travel Med. 2009;16(2):146. author reply 146-7
Monath TP, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005;1(5):207–14.
Lindsey NP, et al. Adverse event reports following yellow fever vaccination, 2007-13. J Travel Med. 2016;23(5):taw045.
Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11(4):427–48.
Rafferty E, et al. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31(49):5798–805.
CDC. Yellow fever vaccine information for healthcare providers. November 2015 [cited 2016 December 14, 2016]; Available from: https://www.cdc.gov/yellowfever/healthcareproviders/vaccine-info.html . Accessed 18 May 2017.
Wu D, Guo CY. Epidemiology and prevention of hepatitis a in travelers. J Travel Med. 2013;20(6):394–9.
Advisory Committee on Immunization, P, et al. Prevention of hepatitis a through active or passive immunization: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-7):1–23.
D'Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis a vaccine (Epaxal) in the elderly. J Travel Med. 2006;13(2):78–83.
Wilder-Smith A. Meningococcal vaccines: a neglected topic in travel medicine? Expert Rev Vaccines. 2009;8(10):1343–50.
WHO. Hepatitis B fact sheet. 2016 [cited 2016 12 DEC 2016]; Available from: http://www.who.int/mediacentre/factsheets/fs204/en/ . Accessed 18 May 2017.
Van Der Meeren O, et al. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: an integrated analysis. Hum Vaccin Immunother. 2015;11(7):1726–9.
WHO. Human rabies: better coordination and emerging technology to improve access to vaccines. 2016 [cited 2016 December 14, 2016]; Available from: http://www.who.int/neglected_diseases/news/human_rabies_better_coordination_and_emerging_technology/en/ . Accessed 18 May 2017.
WHO. Rabies: epidemiology and burden of disease. 2016 [cited 2016 December 14, 2016]; Available from: http://www.who.int/rabies/epidemiology/en/ . Accessed 18 May 2017.
Mills DJ, et al. The immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule--a case series of 420 travelers. J Travel Med. 2011;18(5):327–32.
Ranney M, et al. Rabies antibody seroprotection rates among travelers in Nepal: "rabies seroprotection in travelers". J Travel Med. 2006;13(6):329–33.
Suwansrinon K, et al. Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity. Vaccine. 2006;24(18):3878–80.
Mahon BE, Newton AE, Mintz ED. Effectiveness of typhoid vaccination in US travelers. Vaccine. 2014;32(29):3577–9.
Wagner KS, et al. Effectiveness of the typhoid vi vaccine in overseas travelers from England. J Travel Med. 2015;22(2):87–93.
WHO. Global Health Observatory: number of suspected meningitis cases and deaths reported. 2014 [cited 2017 January 5, 2017]; Available from: http://www.who.int/gho/epidemic_diseases/meningitis/suspected_cases_deaths/en/ . Accessed 18 May 2017.
Ahmed QA, Memish ZA. Hajj 2016: required vaccinations, crowd control, novel wearable tech and the Zika threat. Travel Med Infect Dis. 2016;14(5):429–32.
MacNeil, J. and S. Meyer, Chapter 3: Infectious Diseases Related to Travel Meningococcal Disease, in The Centers for Disease Control and Prevention Yellow Book. 2015.
WHO, Statement on the 10th IHR emergency Committee regarding the international spread of poliovirus. 2016.
CDC, CDC update: interim CDC guidance for travel to and from countries affected by the new polio vaccine requirements. 2016.
Vaughn DW, Hoke CH Jr. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev. 1992;14:197–221.
Yun SI, Lee YM. Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother. 2014;10(2):263–79.
Cramer JP, et al. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO(R) in elderly subjects: open-label, uncontrolled, multi-center, phase 4 study. Vaccine. 2016;34(38):4579–85.
Riddle MS, et al. Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report. Journal of Travel Medicine. 2017;24(Supplement 1):S2–S19.
Nayyar GM, et al. Responding to the pandemic of falsified medicines. AmJTrop Med Hyg. 2015;92(6 Suppl):113–8.
Wyss MN, et al. Management of travelers' diarrhea by local physicians in tropical and subtropical countries--a questionnaire survey. J Travel Med. 2009;16(3):186–90.
Karanika S, et al. Fecal colonization with extended-spectrum Beta-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and Metaanalysis. Clin Infect Dis. 2016;63(3):310–8.
Kantele A, et al. Antimicrobials increase travelers' risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae. Clin Infect Dis. 2015;60(6):837–46.
Banerjee R, et al. Predictors and molecular epidemiology of community-onset extended-spectrum beta-lactamase-producing Escherichia coli infection in a Midwestern community. Infect Control Hosp Epidemiol. 2013;34(9):947–53.
Soraas A, et al. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country. PLoS One. 2013;8(7):e69581.
Thabane M, et al. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol. 2009;104(9):2267–74.
FDA, FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. 2016.
Herxheimer A, Petrie KJ. Melatonin for preventing and treating jet lag. Cochrane Database Syst Rev. 2001;1:CD001520.
Wang PS, et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc. 2001;49(12):1685–90.
Alon D, Shitrit P, Chowers M. Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults. J Travel Med. 2010;17(4):250–5.
Sweeney KR, et al. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin Pharmacol Ther. 1986;40(5):518–24.
Teichman PG, Donchin Y, Kot RJ. International aeromedical evacuation. N Engl J Med. 2007;356(3):262–70.
CDC. CDC: Malaria. 2016 March 24, 2016 [cited 2017 January 6]; Available from: https://www.cdc.gov/malaria/about/faqs.html . Accessed 18 May 2017.
Checkley AM, et al. Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study. BMJ. 2012;344:e2116.
Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med. 2008;359(6):603–12.
McKeage K, Scott L. Atovaquone/proguanil: a review of its use for the prophylaxis of plasmodium falciparum malaria. Drugs. 2003;63(6):597–623.
Grabias B, Kumar S. Adverse neuropsychiatric effects of antimalarial drugs. Expert Opin Drug Saf. 2016;15(7):903–10.
Nika M, et al. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol. 2014;132(10):1199–208.